• Fri. May 24th, 2024

Revolutionizing Personalized Medicine: Adaptive Biotechnologies and Its Groundbreaking Immune Medicine Platform

BySamantha Nguyen

Mar 27, 2024
Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Set for April 2, 2024

Adaptive Biotechnologies Corporation, listed on Nasdaq as ADPT, is a biotechnology company based in Seattle that focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. The company collaborates with biopharmaceutical companies, informs drug development, and develops clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and clinical pipeline focus on diagnosing, monitoring, and treating diseases like cancer, autoimmune disorders, and infectious diseases, with the goal of creating personalized immune-driven clinical products for each patient.

On April 2nd at 1:30 p.m Pacific Time / 4:30 p.m Eastern Time, Adaptive Biotechnologies will be hosting a business update conference call and webcast to provide investors with an overview of their recent progress and future plans. The event will be accessible through the “Investors” section of their website at www.adaptivebiotech.com and will be archived for replay within 24 hours.

Adaptive Biotechnologies believes that the adaptive immune system can be a powerful tool for diagnosing and treating diseases, but its complexity has limited its full utilization. Their immune medicine platform aims to decode and leverage the genetics of the adaptive immune system with scale, precision, and speed. By doing so they aim to create personalized immune-driven clinical products for each patient that can help to diagnose, monitor and treat various diseases like cancer, autoimmune disorders and infectious diseases .

For investors interested in Adaptive Biotechnologies , they can contact Karina Calzadilla , Vice President of Investor Relations at 201-396-1687 or by email at investors@adaptivebiotech.com . For media inquiries , Erica Jones , Associate Director of Corporate Communications can be reached at 206-279-2423 or by email at media@adaptivebiotech.com .

By Samantha Nguyen

As a content writer at newsskio.com, I weave words to craft compelling narratives that captivate readers and bring stories to life. With a keen eye for detail and a passion for storytelling, I strive to create engaging and informative content that resonates with our audience. Whether I'm delving into the latest news trends or exploring unique angles on various topics, my goal is to deliver quality content that informs, entertains, and inspires. Join me on this journey as we uncover the news stories that matter most.

Leave a Reply